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Heparin-induced antibodies and cardiovascular risk in patients
on dialysis
Abstract
The clinical relevance of heparin-induced antibodies (HIA) in the absence of thrombocytopenia remains
to be defined. The aims of this study were (i) to determine the prevalence of HIA in patients treated by
dialysis, (ii) to determine the prevalence of thrombocytopenia and heparin-induced thrombocytopenia
(HIT), and (iii) to test whether HIA are associated with adverse outcomes. Sera from 740 patients
treated by hemodialysis (HD, n=596) and peritoneal dialysis (PD, n=144) were tested for HIA (IgG, IgA
or IgM) by masked investigators at approximately six months after enrolment in the Choices for Healthy
Outcomes in Caring for End-Stage Renal Disease (CHOICE) study. We assessed, with time-to-event
Cox proportional hazards models, whether the presence of HIA predicted any of four clinical outcomes:
arterial cardiovascular events, venous thromboembolism, vascular access occlusion and mortality. HIA
prevalence was 10.3% overall. HIA positivity did not predict development of thrombocytopenia or any
of the four clinical outcomes over a mean follow-up of 3.6 years, with hazard ratios for arterial
cardiovascular events of 0.98 (95% confidence interval 0.70-1.37), venous thromboembolism 1.39
(0.17-11.5), vascular access occlusion 0.82 (0.40-1.71), and mortality 1.18 (0.85-1.64). Chronic
intermittent heparin exposure was associated with a high seroprevalence of HIA. In dialysis patients
these antibodies were not an independent risk factor for cardiovascular events and mortality. Our data do
not suggest that dialysis patients should be monitored for HIA antibodies in the absence of
thrombocytopenia.
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Summary
The clinical relevance of heparin-induced antibodies (HIA) in the
absence of thrombocytopenia remains to be defined.The aims of
this study were (i) to determine the prevalence of HIA in pa-
tients treated by dialysis, (ii) to determine the prevalence of
thrombocytopenia and heparin-induced thrombocytopenia
(HIT), and (iii) to test whether HIA are associated with adverse
outcomes. Sera from 740 patients treated by hemodialysis (HD,
n=596) and peritoneal dialysis (PD, n=144) were tested for HIA
(IgG, IgA or IgM) by masked investigators at approximately six
months after enrolment in the Choices for Healthy Outcomes
in Caring for End-Stage Renal Disease (CHOICE) study.We as-
sessed, with time-to-event Cox proportional hazards models,
whether the presence of HIA predicted any of four clinical out-
comes: arterial cardiovascular events, venous thromboembol-
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ism,vascular access occlusion and mortality.HIA prevalence was
10.3% overall. HIA positivity did not predict development of
thrombocytopenia or any of the four clinical outcomes over a
mean follow-up of 3.6 years, with hazard ratios for arterial car-
diovascular events of 0.98 (95% confidence interval 0.70–1.37),
venous thromboembolism 1.39 (0.17–11.5), vascular access oc-
clusion 0.82 (0.40–1.71), and mortality 1.18 (0.85–1.64).
Chronic intermittent heparin exposure was associated with a
high seroprevalence of HIA. In dialysis patients these antibodies
were not an independent risk factor for cardiovascular events
and mortality. Our data do not suggest that dialysis patients
should be monitored for HIA antibodies in the absence of
thrombocytopenia.
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Introduction
Heparin-induced thrombocytopenia (HIT) is an acquired throm-
bocytopenia mediated by anti-heparin/platelet factor 4 (PF4)
antibodies in the setting of heparin therapy. Affected patients are
at substantial risk for arterial and venous thrombotic compli-
cations (1–4). While HIT is defined as thrombocytopenia in the
presence of heparin-induced antibodies (HIA), many patients
exposed to heparin acquire HIA in the absence of thrombocy-
topenia. Up to 50% of cardiac surgery patients will develop HIA,
although only 2% of these patients will also have thrombocy-
topenia (5). Some reports suggest that HIA even in the absence
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of thrombocytopenia are an independent predictor of myocardial
infarction in patients with acute coronary ischemic syndromes
(6), although others have not confirmed this (7).
Patients with chronic kidney disease (CKD) are at high risk
for cardiovascular events. Five-year survival of patients on he-
modialysis (HD) is less than 50% (8). More than half of this mor-
tality is related to myocardial infarction alone, but other arterial
events including stroke and peripheral artery disease are also
highly prevalent. Venous thromboembolic events also occur in
HD patients, but data regarding incidence are scarce (9, 10). Ad-
ditionally, vascular access occlusion occurs in 33–56% of HD
patients and leads to annual costs exceeding $1 billion in the
United States (11, 12).
Known cardiovascular risk factors do not entirely account for
the high cardiovascular disease-related morbidity and mortality
in these patients (13). Several reports, most of them based on
small patient cohorts, have analysed the frequency of HIA in pa-
tients chronically exposed to heparin in the setting of HD. How-
ever, these studies were not designed to assess the clinical rel-
evance of these antibodies. Hence, we sought to test the hypoth-
esis that HIA are a “non-traditional” cardiovascular risk factor in
this population using time to event analysis. The aims of this
study were (i) to determine the prevalence of HIA in patients
treated by dialysis, (ii) to determine the prevalence of throm-
bocytopenia and HIT in this group of patients, and (iii) to test
whether HIA are associated with adverse outcomes including ar-
terial cardiovascular events, venous thromboembolic events,
events of vascular access occlusion, and mortality.
Methods
Patient population and blood sampling
The study subjects were a subpopulation of patients participating
in the Choices for Healthy Outcomes in Caring for End-Stage
Renal Disease (CHOICE) Cohort Study (14,15). CHOICE is a
national, prospective cohort study of incident HD and peritoneal
dialysis (PD) patients initiated in 1995 to investigate treatment
choices of modality and dose and outcomes of dialysis care.
From October 1995 to June 1998, 1,041 (767 HD and 274 PD)
patients were enrolled from 81 dialysis clinics associated with
Dialysis Clinic, Incorporated (DCI, Nashville, TN, USA), New
Haven CAPD (New Haven, CT, USA), and the Hospital of Saint
Raphael (New Haven, CT, USA) (Fig. 1). All study participants
were incident kidney failure patients starting outpatient dialysis,
were over 17 years of age, and spoke English or Spanish. Patients
were enrolled a median of 45 days from initiation of chronic
dialysis (98% within 4 months). The mean duration of follow-up
was 3.6 years (5
th
and 95
th
percentiles, 5.8 months and 9.1 years,
respectively). Follow-up was complete (100%) in regard to car-
diovascular mortality. The prospectively designed study was ap-
proved by the Johns Hopkins University School of Medicine In-
stitutional Review Board prior to the initiation of HIA testing.
Routine blood draw sera, collected as close as possible to six
months after the first dialysis (mean time to testing 5.7 months,
5
th
and 95
th
percentile: 71 days and 1.1 years), were available
from 740 dialysis (HD and PD) patients. HD patients were
chronically exposed to heparin during dialysis, whereas PD pa-
tients putatively were not. The 301 patients that could not be in-
cluded in the study due to lack of available serum samples had
similar baseline characteristics compared to patients that were
included in the study. The excluded patients did not differ by sex,
hypertension, diabetes, smoking status, albumin, cholesterol,
triglyceride levels and body mass index (BMI). They did tend to
be younger, were less likely to be white, were less likely to have
an elevated comorbidity score (ICED =3; see “baseline data col-
lection” for definition) and had higher creatinine, higher low-
density lipoproteins (LDL) cholesterol and lower C-reactive pro-
tein (CRP).
Outcomes
Our outcomes of interest were thrombocytopenia and four clini-
cal outcomes. Platelet counts were obtained from routine
monthly blood draw data provided by the clinics. Thrombocy-
topenia was defined as a platelet count below 150 G/l
(150,000/µl) or a decrease of 50% or more from a previous pla-
telet count. Mortality was ascertained from dialysis centre re-
ports, medical records, and data from the CMS and the National
Death Index (NDI). Arterial cardiovascular events included any
of the following events during the follow-up period: myocardial
infarction, cerebrovascular accident, coronary artery bypass
graft, percutaneous coronary angioplasty, peripheral artery by-
pass, amputation, abdominal aortic aneurysm repair, carotid
endarterectomy, and sudden coronary death. These events were
identified in hospitalisation records, reviewed and adjudicated
Figure 1: Consolidated standards of reporting trials (CON-
SORT) diagram of patient enrolment. The diagram shows the
numbers of patients who met the criteria of inclusion in or exclusion
from the study. Quality control samples included hemodialysis (n=40)
and peritoneal dialysis patients (n=9).
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by two members of the study’s outcomes committee using uni-
formly applied criteria modified from the Cardiovascular Health
Study (16), HEMO study (17), or, in the absence of an adjudi-
cated record, from CMS hospitalisation data. Deep vein throm-
bosis and pulmonary embolism events were identified in CMS
hospitalisation data as defined by ICD-9-CM codes (451.1x,
451.2, 451.81, 451.83, 451.89, 452.x, 453.x and 415.1x). Finally,
vascular access information was obtained through review of dis-
charge summaries, dialysis flow sheets, and dialysis clinic prog-
ress notes, as described elsewhere (18). All vascular access oc-
clusion events were reviewed, and only those coded as thrombo-
sis-related were used as outcomes in this study.
Baseline data collection
Demographic characteristics, primary cause of kidney failure,
and date of first chronic dialysis were ascertained from the
Centres for Medicare & Medicaid Services (CMS) Medical Evi-
dence Form (Form 2728), which was completed at initiation of
chronic dialysis. Race was categorised as black, white, or other
(including Native American and Asian). Comorbidity assess-
ment was performed at enrolment using the Index of Coexistent
Disease (ICED), a composite scoring system based on 19 medi-
cal and 11 physical impairment categories (19). The scores are
compiled into a summary score representing mild (0 or 1), mod-
erate (2), or severe comorbidity (3).
Assay for HIA
We utilised a standard enzyme-linked immunosorbent assay
(ELISA) for HIA, the GTI-PF4 enhanced assay (Genetic Testing
Institute, Waukesha, WI), which detects IgG, IgM and IgA di-
rected against platelet factor 4 (PF4) bound to polyvinylsulfonate
(6,20).All assays were performed in duplicate (45 samples, a posi-
tive control, a negative control and a blank per each 96-well plate)
by blinded investigators and according to the manufacturer’s in-
structions. Absorbance for positive controls had to be ≥1.8 units,
negative controls ≤0.3 units; if the mean of the sample absorbance
≥0.4 units, the test was considered positive.To detect false-positive
results, such as when antibodies are directed against heparin alone
or when antibodies are non-specific, the heparin neutralisation
procedure (HNP) was performed according to the manufacturer’s
instructions.An inhibition of a positive result by more than 50% in
the presence of heparin is considered confirmatory for HIA.
Quality control, correction procedure, and heparin
neutralisation
ELISA results were validated on a per-plate and per-assay basis.
Plates were considered valid if no more than four sample results
exceeded the limits for the coefficient of variability (CV>15%)
and if the positive/negative control criteria were met. For individ-
ual assays, the manufacturer tolerates 20% variability of the
mean of the two samples; we applied a more stringent CV cri-
terion of 15%. Any individual sample with a coefficient of varia-
bility exceeding 15% was considered invalid if the mean absorb-
ance was ≥0.150.Tests with a mean absorbance value <0.15 were
considered to be valid, regardless of the CV, as they were clearly
negative. Forty-nine blinded quality control samples were ana-
lysed. Due to the quality control criteria, 0.6% of samples
(5/789) but no (0/18) whole plates had to be retested. Agreement
for 49 pairs of blinded quality control samples was 90% with a
kappa value of 0.4.
In agreement with the manufacturer’s specifications intra-
plate variability of results was minimal (mean coefficient of
Figure 2:Temporal aspects
of HIA prevalence. For the
740 patients in whom analys-
able samples were available,
some did not have samples
available at six months. In
these cases the temporally
closest available samples were
chosen. Depicted is the preva-
lence of HIA according to
sample collection time relative
to start of dialysis: <90 days
(n=75), 91–180 days (n=523)
and >180 days (n=142).
Corrected ELISA results were
used to determine prevalence.
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variability (CV) for positive controls was 1.86 ± 1.32%, range
0.06–4.83%). We observed an interplate variability range for
positive controls of 2.3–3.6. According to the manufacturer’s
specifications any result ≥1.8 is acceptable for positive controls,
resulting in a theoretical range of 1.8–3.6.This illustrates that the
same sample measured on different plates can give results that
vary by 64% (as observed) or 100% (in theory). Our results sug-
gest that, due to the assay characteristics, results from different
plates can only be evaluated on a categorical scale (positive/
negative).To permit evaluation of optical density (OD) results on
a continuous scale we designed a correction procedure that
allowed us to compare OD values stemming from different
plates. For this procedure mean OD values were calculated for all
plates after exclusion of extreme OD values (<0.1 and >1.0). The
mean OD values were normalised to the mean OD of an index
plate defined to have a correction coefficient of 1. All results on
an individual plate (including the extreme values) were then
multiplied by the plate’s correction coefficient. When this per-
plate correction procedure was performed, the quality control
parameters improved to 93% agreement and a kappa value of
0.6, respectively.
Data analysis
We compared patient characteristics by HIA status using Pear-
son’s Chi
2
tests for categorical variables and analysis of variance
for continuous variables. We used logistic regression to examine
the association between HIA status and incidence of thrombocy-
topenia. Cox proportional hazards models were used to assess
the strength and independence of an association between HIA
status and arterial cardiovascular events, deep vein thrombosis/
pulmonary embolism, vascular access occlusion, and mortality.
Relative hazards for these events were calculated by HIA status
using time from first dialysis to death or censoring (at transplant,
loss to follow-up, or closeout) as the survival time variable. Vari-
ables were chosen for adjustment (e.g. race, ICED, age at enrol-
ment, and baseline albumin level) in the regression models based
on either their demonstration to be confounders or prior evidence
of their association with the outcome in question. All analyses
were performed using Stata version 8.1 (StataCorp, College
Station, TX, USA).
Patients at the same clinic cannot be considered independent
observations (21). We accounted for this by obtaining robust
variance-covariance matrix estimates in all logistic regression
and Cox proportional hazards models (stata option cluster) (22).
HIA-positive HIA-negative
N (%) 076 (10.3) 664 (89.7)
Age (years) 059 056
Sex (f : m) 0.51 : 0.49 0.47 : 0.53
Race (%):
– Caucasian 053.9 063.1
– Other 005.3 005.7
ICED: 1/2/3 (%) 024/45/31 34/38/28
Albumin (g/dl) 003.60 (3.51–3.69) 003.63 (3.60–3.66)
Diabetes (%) 057.9 054.8
Cholesterol total (mg/dl) 186.7 (174.1–199.3) 188.2 (184.5–192.0)
Cholesterol LDL (mg/dl) 082 (73–91) 087 (84–90)
Triglycerides (mg/dl) 209.9 (177.9–241.9) 195.4 (185.6–205.2)
Body mass index 027.8 (25.8–29.7) 026.9 (26.4–27.4)
C-reactive protein (mg/ml) 003.65 003.91
Baseline time of HIT antibody testing was at a mean of 5.7 months with 5
th
and 95
th
percentiles at
71 days and 1.1 years, respectively. HIT: heparin-induced thrombocytopenia; f: female, m: male;
ICED: index of coexistent disease, comorbidity score; ES: ever-smoker includes current and former
smokers; LDL low-density lipoprotein. Where applicable 5
th
and 95
th
percentile values are given in
parentheses.
Creatinine (mg/dl) 007.22 (6.66–7.77) 007.49 (7.29–7.68)
Smoking status (% ES) 067.1 058.3
Hypertension (%) 097.4 095.6
– African American 040.8 031.2
Table 1: Patient characteristics by HIA status at baseline.
HD PD Overall
N
– HIA-positive (%) 063 (10.6) 013 (9.3) 076 (10.3)
– HIA positive by HNP 053 013 066
– HIA-negative 533 131 664
Mean platelet count
– HIA-positive 230 ± 62 265 ± 77 226 ± 67
– HIA-negative 242 ± 77 298 ± 65 242 ± 75
Mean (median) absorbance
– HIA-positive 0.70 ± 0.38 (0.57) 0.71 ± 0.43 (0.55) 0.70 ± 0.39 (0.57)
– HIA-negative 0.17 ± 0.09 (0.16) 0.15 ± 0.08 (0.14) 0.17 ± 0.09 (0.15)
N: number of patients; HNP: number of patients with results confirmed by heparin neutralisation procedure; HD: haemodialysis; PD:
peritoneal dialysis.
Table 2: Mean platelet count and mean
absorbance by HIA status and treat-
ment modality.
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Results
HIA prevalence
Antibodies directed against heparin/PF4 were detected in nearly
20% of patients early after treatment initiation (Fig. 2) and at six
months following initiation of dialysis seventy-six of 740
(10.3%) patients had a positive HIA assay (Table 1). In samples
taken at later time points after HD initiation, the prevalence was
lower. For patients receiving PD, the prevalence was stable over
time at 9%. Patient characteristics by antibody positivity at study
inclusion are depicted in Table 2. There were no significant dif-
ferences between the HIA-positive and -negative groups by
demographics, comorbidity score, cardiovascular risk factors, or
relevant laboratory data with the exception of a smoking history
at study inclusion.
HIA and thrombocytopenia
Mean platelet counts were lower in HIA-positive patients but did
not differ significantly from those in HIA-negative patients at the
time of antibody testing (Table 2). The presence of HIA did not
predict subsequent thrombocytopenia at three (p=0.89), six
(p=0.56), or nine months (p=0.76) after measurement.
HIA and clinical outcome
Survival analyses showed no association between positive HIA
status and any of the clinical outcomes (Table 3). A total of 372
arterial events were recorded in 678 individuals. The cor-
responding numbers were 7 and 737 for venous thromboembol-
ism, 86 and 601 for venous access occlusion, and 448 and 732 for
mortality. The discrepancy between the number of patients in the
study (740) and the number of individuals cited above is due to
events taking place prior to HIA testing and missing covariates.
The highest hazard ratio (HR) was 1.4 for the association be-
tween HIA and venous thromboembolism but the confidence in-
terval (CI) was wide and included 1.0. Unadjusted and adjusted
results yielded similar results.
Survival analysis performed on corrected (see per-plate cor-
rection procedure under methods; shown) and uncorrected data
(not shown) yielded the same results. The results of the survival
analyses were also the same when we analysed all positive
samples (n=76) or only the ones confirmed by HNP (n=66).
HIT and HIT-related thrombosis
Nine patients had results compatible with HIT, defined as a posi-
tive HIA assay and thrombocytopenia in the ensuing three
months (9/740, 1.2%). The mean minimal platelet count of the
potential HIT patients during their thrombocytopenic episode
was 124 (range 106–147). One of the nine patients had throm-
bocytopenia as defined by a relative drop of platelet count by
more than 50%.All nine patients with potential HIT were receiv-
ing HD. One patient with potential HIT had a venous throm-
boembolic event (1/740, 0.13%) resulting in a HR of 13.7 (95%
CI 1.63–115.5) for HIT and thrombosis. Six out of nine potential
HIT patients’ (including the patient with thrombosis) ELISA re-
sults were confirmed by the HNP.
Discussion
We have demonstrated that approximately 10% of CKD patients
treated by dialysis develop HIA at six months. Most previous
studies suggested a lower prevalence of HIA in HD patients
ranging from 0 to 8.8% (23–31) with one exception at 17.9%
(32). In these studies, screening was often limited to patients
with thrombocytopenia or thrombotic complications. Fur-
thermore, the assay used to detect HIA and timing of the test var-
ied across studies. While most of these studies have not shown a
correlation of HIA with adverse outcomes (29, 32), others have
(30, 31). Limitations of these studies included small patient co-
horts (n<100) (23, 24, 27, 29–31), fewer than 10 HIA positive
patients (23–27, 30, 31), or study design that not did allow pros-
pective recording and assessment of multiple clinical outcomes.
None of these studies reported quality control and/or perform-
ance of HNP.
In the absence of thrombocytopenia, we found that HIA posi-
tivity was not associated with adverse outcomes including arter-
ial cardiovascular events, venous thromboembolic events, vascu-
lar access occlusion, and mortality. Our data, as well as data from
prospective studies in populations without CKD (5, 7, 20, 33)
and with CKD (24, 29), support the hypothesis that adverse car-
diovascular events associated with HIA require the activation of
platelets by HIA, which manifests as thrombocytopenia. Our
findings are not consistent with the model in which HIA-me-
diated platelet activation is bypassed and in which there is direct
HIA-mediated activation of target cells such as endothelial cells
or monocytes (1, 2, 34).
There is a recently published study by Carrier et al. which re-
ports that IgG specific HIA found in nine of 419 patients (uni-
variate HR 2.40, 95% CI 0.98 –5.89; multivariate HR 2.68,
95%CI 1.08–6.63) are associated with increased mortality in HD
patients.The authors also looked at non IgG specific HIA – using
the same test that we used – in their patient population. No as-
sociation between non-specific HIA and mortality was found
(35). Our study confirms the results of Carrier et al. in that 12.9%
were HIA positive (using the non IgG-specific assay) while we
found 10.3% seropositive patients. The study by Carrier et al.,
however, does not report on platelet count. One can thus not
evaluate and differentiate the outcome of HIA-positive throm-
bocytopenic patients, i.e. those with true HIT from that of HIA
positive non-thrombocytopenic patients. We looked at HIA
status and platelet count and found no increased mortality of
Hazard ratio 95% CI No. of events
Arterial cardiovascular
events*
0.98 0.70 – 1.37 372
Venous
thromboembolism
1.39 0.17 – 11.5 007
Vascular
access occlusion
0.82 0.40 – 1.71 086
Mortality
†
1.18 0.85 – 1.64 448
CI: confidence interval; *adjusted for age, sex, race, dialysis modality, and smoking status;
†
adjusted
for age, race, albumin and comorbidity score (ICED).
Table 3: Adjusted risk of adverse events by the presence of HIA
at baseline.
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other adverse outcome in the HIA positive non-thrombocyto-
penic group. There is literature showing that IgG-specific HIA
testing offers enhanced test characteristics as compared to non
IgG-specific HIA tests (36). However, there are also data show-
ing that non IgG-mediated forms of HIT occur (37). This to-
gether with the aspect that at the time of study design there were
only two marketed, clinically validated and Food and Drug Ad-
ministration (FDA) approved tests available (both were non IgG-
specific, one of which we chose for this study) motivated our
choice of HIA assay.
In this study we examined 740 patients, including nearly 600
HD patients. HIA testing was performed by blinded investigators
using a standardised protocol with rigorous quality control, and
HNP was performed to rule out false-positive results. Clinical
outcomes were collected from multiple sources, and all events
were validated. Limitations of our study include a potential
underestimation of the frequency of HIT-related events. As we
tested HIA status at six months after HD initiation, any cardio-
vascular events in patients whose seroconversion occurred after
the initial testing would be missed. However, late seroconversion
is less likely than seroconversion close to the time of heparin
initiation. Finally, we did not assess the persistence of HIA until
the time of the event.
Previously, one study described temporal aspects of HIA
prevalence in patients acutely exposed to heparin (20). Only li-
mited data are available for chronically exposed patients. Mean
time between starting of HD and development of HIT in a UK
survey was 61 days (range 5–390) (38). We did not serially fol-
low up our dialysis patients, our study nonetheless gives insight
into the temporal aspects of HIA seroconversion in this type of
heparin exposure (Fig. 2). The above mentioned findings are
compatible with a model in which a subset of heparin-exposed
patients have a propensity to develop HIA and in which a “time
window” exists during which HIA formation is most likely to
occur. According to this hypothesis the large majority of patients
will develop HIT when both conditions are met. The “time
window” may vary depending on duration and type of heparin
exposure as well as the clinical setting.As the UK survey and our
data suggest chronic intermittent exposure in dialysis patients
may lead to a time window of several weeks to months, whereas
for acute heparin exposure the time of maximum risk appears to
be from day 4 to day 14 (4).
The high prevalence of HIA in PD patients remains unex-
plained. All HIA in PD patients were shown to be heparin-spe-
cific through the HNP, which detects false-positive results (see
Table 2). PD patients are not routinely exposed to therapeutic
doses of heparin. They may, however, be exposed to heparin in
intravenous flushes, heparin additives to dialysis fluids, heparin
prophylaxis at time of immobilisation and other situations with
increased venous thromboembolic risk or also during angio-
graphic procedures.
We conclude that although there is a high prevalence of HIA
of the IgG, IgA or IgM class, these antibodies directed against
heparin/PF4 (as detected in a non IgG-specific assay) in the ab-
sence of thrombocytopenia are not associated with cardiovascu-
lar events or increased mortality in patients on dialysis. Our re-
sults do not support the hypothesis that HIA lead to adverse clini-
cal outcomes in the absence of platelet activation. In addition to
giving insight into the pathophysiology of HIT, our data have im-
plications for monitoring and therapeutic guidelines. Firstly, our
data suggest that following the initiation of dialysis monitoring
of HIA antibodies is not warranted in patients in the absence of
thrombocytopenia or clinical evidence suggestive of HIT. Sec-
ondly, our data provide no evidence that would justify switching
from heparin to an alternative potentially more expensive antico-
agulant in dialysis patients who are HIA positive and non-throm-
bocytopenic. Finally, the data provide reassurance that the induc-
tion of HIA by chronic intermittent exposure to heparin is not as-
sociated with a high risk of adverse outcomes in patients with
CKD treated by dialysis.
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